These discoveries provide guidance for precision radiotherapy in prostate cancer: PARP1-EJ repair switching can serve as a criterion for patient selection, while effectively inducing tumor cell senescence is a key mechanism for successful treatment. Here, PARP1 is linked to prostate carcinoma.